RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk
RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk
加拿大皇家银行将Aptose Biosciences的目标股价从23美元下调至18美元,保持跑赢大盘,存在投机风险
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册